1.Research progress on deep learning-based computer-aided diagnosis of thyroid nodules using ultrasound imaging.
Xinyuan ZHOU ; Min QIU ; Jiangfeng SHANG ; Guohui WEI
Journal of Biomedical Engineering 2025;42(5):1069-1075
Thyroid nodules are a common endocrine disorder, and their early detection and accurate diagnosis are crucial for the prevention of thyroid cancer. However, the highly heterogeneous morphology and boundaries of thyroid nodules pose significant challenges to their precise identification and classification. Traditional diagnostic approaches rely heavily on physicians' experience, which increases the risk of misdiagnosis and missed diagnoses. With the rapid advancement of computer-aided diagnosis (CAD) technologies, applying deep learning algorithms to the analysis of thyroid nodule ultrasound images has shown great potential. This paper reviews the latest research progress on deep learning-based CAD methods for thyroid nodules, with a focus on their applications in image preprocessing, segmentation and classification. The advantages and limitations of current techniques are analyzed, and potential future directions are discussed. This review aims to highlight the potential of deep learning in thyroid nodule diagnosis and to provide a foundation for selecting feasible pathways for future clinical applications.
Humans
;
Thyroid Nodule/diagnostic imaging*
;
Deep Learning
;
Ultrasonography/methods*
;
Diagnosis, Computer-Assisted/methods*
;
Algorithms
;
Thyroid Neoplasms/diagnostic imaging*
;
Image Processing, Computer-Assisted/methods*
2.Fermentation improves the immune function of the Astragalus membranaceus (Fisch.) Bunge stem and leaf
Zhixun Li ; Mingyue Jia ; Mengke Sheng ; Qing Zhou ; Xinhui Peng ; Weishuo Ren ; Kaijie Hu ; Xinyuan Shi
Journal of Traditional Chinese Medical Sciences 2025;2025(2):191-200
ObjectiveTo improve the efficacy of Astragalus membranaceus (Fisch.) Bunge (A. membranaceus, Huang Qi), and to further develop and utilize it, fermentation technology was applied to the stem and leaf of A. membranaceus to enhance its immune function.MethodsIn this study, we fermented A. membranaceus stem and leaf (ASL) with probiotics and investigated its immune function. Firstly, we screened suitable strains for ASL fermentation and optimized the fermentation process. Secondly, we determined the antioxidant capacity of fermented ASL and its effect on inflammation in mouse monocyte-macrophage cell. Finally, the immunocompromised mice were treated with fermented ASL to investigate the changes in their immune ability.ResultsAmong the 10 selected probiotics, Lactobacillus plantarum was the most suitable strain for ASL fermentation. After optimization of the fermentation process, the content of saponins in fermented ASL was significantly increased. The fermented ASL exhibited strong anti-inflammatory and antioxidant activities in vitro. The in vivo immune efficacy improved by promoting the development of the spleen and thymus, as well as raising the immunoglobulin M, tumor necrosis factor-α, and interleukin-1β levels of in the serum.ConclusionThis study contributes to developing the non-medicinal parts of A. membranaceus, expands its medicinal resources, highlights the potential of fermentation technology to enhance these parts, and provides a reference for further development. Based on this approach, we can promote using non-medicinal parts of herbal medicines, minimize drug waste, and offer a reference for developing non-medicinal components in Chinese herbal medicines.
3.Clinical phenotype and genetic analysis of a child with CAKUTHED syndrome due to variant of PBX1 gene.
Jiao TANG ; Chuan ZHANG ; Ruiqiong YANG ; Xinyuan TIAN ; Bingbo ZHOU ; Yupei WANG ; Ling HUI
Chinese Journal of Medical Genetics 2025;42(12):1471-1476
UNLABELLED:
OBJECTIVE:To explore the clinical characteristics and genetic etiology of a child with CAKUTHED syndrome.
METHODS:
A child who was admitted to the neonatal department of Gansu Provincial Maternal and Child Health Care Hospital due to "neonatal asphyxia" in May 2021 was selected as the study subject. Genomic DNA was extracted from peripheral venous blood samples from the child and his parents, and whole exome sequencing (WES) was carried out. Sanger sequencing was used to verify the candidate variant of the PBX1 gene. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the pathogenicity of candidate variants was rated. This study was approved by the Medical Ethics Committee of the Hospital [Ethics No.: 2021GSFY (65)].
RESULTS:
The proband, a male neonate, manifested renal dysplasia, congenital heart disease, pulmonary dysplasia, mediastinal hernia, cryptorchidism, and clavicle dysplasia. WES revealed that he had harbored a heterozygous c.863G>A (p.Arg288Gln) missense variant in exon 6 of PBX1 gene, which resulted substitution of Arginine at position 288 by Glutamine, for which both parents were of the wild type. The variant was unreported previously and rated as pathogenic (PS2+PM1+PM2_Supporting+PP2+PP3) based on the ACMG guidelines.
CONCLUSION
The c.863G>A variant of the PBX1 gene probably underlay the pathogenesis in the proband. Above finding has enriched the mutational spectrum of the PBX1 gene.
Humans
;
Male
;
Pre-B-Cell Leukemia Transcription Factor 1/genetics*
;
Phenotype
;
Infant, Newborn
;
Exome Sequencing
;
Mutation, Missense
;
Heart Defects, Congenital/genetics*
;
Abnormalities, Multiple/genetics*
4.Construction and evaluation of berberine/piperine co-loaded self-microemulsion drug delivery system
Chunmei LI ; Jiawen LIU ; Xinyuan ZHANG ; Changsheng ZHOU
China Pharmacy 2024;35(24):2990-2997
OBJECTIVE To prepare berberine/piperine co-loaded self-microemulsion drug delivery system (BBR/PIP- SMEDDS), evaluate its physicochemical properties, in vitro release and pharmacokinetic characteristics. METHODS The drug loading mass ratio of berberine (BBR) and piperine (PIP) in the preparation was determined by the everted intestinal sac method. The oil-phase, emulsifier and co-emulsifier were determined by solubility detection, compatibility evaluation and pseudo-ternary phase diagram, respectively. The formulation of blank self-microemulsion drug delivery system (SMEDDS) was optimized and verified by central composite design-response surface methodology with the amount of oil-phase and the mass ratio of emulsifier to co-emulsifier as factors, and the comprehensive score of particle size and Zeta potential as response value. According to the optimal prescription, BBR/PIP-SMEDDS was prepared by adding excessive BBR and PIP raw materials under magnetic stirring, and its physicochemical properties, in vitro release behavior and pharmacokinetic characteristics in rats were investigated. RESULTS The drug loading mass ratio of BBR and PIP was 1∶1. The optimal prescription included oil-phase (ethyl oleate) accounted for 18.54%, emulsifier (Tween-80) accounted for 52.16%, and co-emulsifier (polyethylene glycol 400) accounted for 29.30%. Three verification experiments showed that the average particle size of blank SMEDDS was (16.49±0.49) nm; the Zeta potential was (-16.22±0.77) mV; the comprehensive score was 0.97, the relative deviation of which from the predicted value (0.95) was 2.11%. The prepared BBR/PIP-SMEDDS was an oil-in-water microemulsion, which was a golden yellow oily liquid with a spherical shape. The average particle size was (32.90±0.38) nm, and the Zeta potential was (-19.17±0.70) mV. The encapsulation efficiency of BBR was (90.44±0.88)% , and the drug loading was (10.18±0.17) mg/g. The encapsulation efficiency of PIP was (87.48±1.13)%, and the drug loading was (9.41±0.17) mg/g. BBR/PIP-SMEDDS had good stability at low temperature (4 ℃ ) in the dark, centri-fugation and dilution. The results of in vitro release showed that the cumulative release percentage of BBR in simulated intestinal fluid for 24 h was significantly higher than that of the raw drug after the preparation of SMEDDS. The pharmacokinetic results in rats showed that the peak concentration and area under the drug- concentration time curve (AUC0-)t of BBR/PIP-SMEDDS were 4.61 and 7.07 times higher than those of the raw drug respectively, and the relative bioavailability was 707.484%. CONCLUSIONS BBR/PIP-SMEDDS is successfully prepared, and the in vitro release and bioavailability of the preparation are greatly improved compared with the raw material.
5.A prospective cohort study on the relationship between serum FGF23 and the risk of heart failure and death in end-stage renal disease patients
Xiaoxia WANG ; Xinyuan ZHOU ; Xiangjie YANG ; Runzhe ZHOU ; Yuqing MENG ; Dingxin ZHANG ; Jin ZHANG ; Ying WANG
Acta Universitatis Medicinalis Anhui 2024;59(5):874-880
Objective To explore the correlation between serum fibroblast growth factor-23 (FGF23) concentration and heart failure and all-cause death in patients with end-stage renal disease (ESRD).Methods The prospective cohort study design was used in the present study.The ESRD patients who were admitted to the department of ne-phropathy in the Hospital and without heart failure symptoms were recruited in this study.The data of patients was collected through baseline questionnaires, physical examinations, echocardiography, and laboratory examinations.The serum FGF23 levels were measured by enzyme-linked immunosorbent assay (ELISA) .The follow-up time was 2 years.The onset of heart failure (ACC/AHA stage C-D) and all-cause death were composite endpoint events.The Cox proportional risk model was used to explore the risk factors of outcome events.Through subgroup analyses and interaction analyses, further exploration was conducted to determine whether there was heterogeneity in the as-sociation between FGF23 and outcome events in different subgroups.Results Ultimately,107 ESRD patients were included in this study, with an average age of (52.00 ± 12.51) years.There were 39 males (36.45%), and the median follow-up time was 23 months (21, 25 months).There were 32 (29.9%) outcome events, of which 22 (20.6%) onset of heart failure and 10 (9.3%) all-cause of deaths.The results of this study showed that the con-centration of FGF23 in the outcome event group was significantly higher than that in the non-event group [ (4.40 ± 1.16) pmol/ml vs (3.85 ± 0.82) pmol/ml,P<0.05].The Cox proportional risk model showed that the elevated FGF23 was associated with increased risk of the composite endpoint events in ESRD patients (HR=1.730 , 95%CI:1.164-2.570 , P=0.007) .Subgroup analyses showed that there was an interactive effect between FGF23 levels and gender on the risk of cardiovascular outcome events.Especially in male ESRD patients, the increased FGF23 level was correlated with a higher risk of cardiovascular events (P-interaction <0.05).Conclusion Elevated serum FGF23 is an independent risk factor for the onset of heart failure and all-cause of mortality in ESRD patients, especially in male patients.
6.Genetic analysis of eighteen patients from Gansu province with Tetrahydrobiopterin deficiency
Chuan ZHANG ; Xinyuan TIAN ; Yupei WANG ; Panpan MA ; Xue CHEN ; Bingbo ZHOU ; Qinghua ZHANG ; Shengju HAO ; Ling HUI ; Zhe YIN ; Zongfu CAO
Chinese Journal of Medical Genetics 2024;41(2):129-133
Objective:To explore the genetic basis of eighteen patients with tetrahydrobiopterin deficiency (BH4D) from Gansu Province.Methods:Eighteen patients diagnosed with BH4D at Gansu Provincial Maternal and Child Health Care Hospital from January 2018 to December 2021 were selected as the study subjects. Whole exome sequencing was carried out, and candidate variants were verified by Sanger sequencing.Results:All of the thirty-six alleles of the eighteen patients were successfully determined by molecular genetic testing. Sixteen patients were found to harbor variants of the PTS gene, and two had harbored variants of the QDPR gene. Ten variants were detected in the PTS gene, with the most common ones being c. 259C>T (34.38%) and c. 286G>A (15.63%). Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the c. 259C>T was classified as a pathogenic variant, whilst the c. 286G>A, c. 166G>A, c. 200C>T, c. 272A>G, c. 402A>C, c. 421G>T, c. 84-291A>G and c. 317C>T were classified as likely pathogenic variants. A novel c. 289_290insCTT variant was classified as likely pathogenic (PM1+ PM2_Supporting+ PM3+ PP3+ PP4). The two variants (c.478C>T and c. 665C>T) detected in the QDPR gene were both classified as variants of uncertain significance (PM1+ PM2_Supporting+ PP3+ PP4). Conclusion:Genetic testing has clarified the pathogenic variants in these BH4D patients, which has enabled timely and accurate clinical intervention and treatment, and provided a reference for genetic counseling and reproductive guidance for their families.
7.Research progress in hip-preserving modalities for early osteonecrosis of the femoral head in young and middle-aged patients
Xiaoyang SONG ; Haoqiang ZHANG ; Yongjie QIAO ; Yonggang CHENG ; XinYuan YU ; Jinpeng LOU ; Hao LIU ; Ziyao LI ; Bo XU ; Shenghu ZHOU
Chinese Journal of Trauma 2023;39(2):171-177
Osteonecrosis of the femoral head (ONFH) is one of the common and difficult-to-treat orthopedic diseases caused by a variety of factors that lead to abnormal blood flow to the femoral head, which in turn leads to deformation and collapse of the femoral head and eventually results in severe hip joint dysfunction. The key to the treatment is early diagnosis and correct treatment according to the stage classification and active prevention of further aggravation of ONFH aiming to delay or avoid hip replacement surgery in young and middle-aged patients. At present, there are various non-surgical and surgical hip-preserving modalities for early ONFH, designed to slow down the progression of the disease, prevent the femoral head from collapsing and stop the mild collapse. In recent years, with the emergence and development of bone reconstruction biomaterials, artificial bone reconstruction after scraping of ONFH lesions has shown great potential in the treatment of early ONFH. The authors review the research progress in hip-preserving modalities for early ONFH in young and middle-aged patients from non-surgical and surgical perspectives, hoping to provide a reference for clinical treatment of early ONFH.
8.A case report of prostate mucinous adenocarcinoma
Xinyuan YU ; Xiao LI ; Hongjun ZHAO ; Bao LI ; Huimin SUN ; Quan ZHOU
Chinese Journal of Urology 2023;44(3):224-225
Mucinous adenocarcinoma of the prostate is a rare pathological type of prostate cancer. We reported one case. The patient went to see a doctor because of intermittent hematuria. He was diagnosed as prostate adenocarcinoma before operation. He underwent laparoscopic radical prostatectomy. Postoperative pathological examination showed mucinous adenocarcinoma of the prostate. The patient was followed up for six months. Imaging showed no signs of recurrence and metastasis with normal tPSA.
9.The construction and management of scientific research institutes portal websites
Xinyuan ZHANG ; Yue ZHOU ; Xueshi MAO
Chinese Journal of Medical Science Research Management 2022;35(4):246-251
Objective:Exploring effective methods of information management in the practice of constructing practical and beautiful websites.Methods:Building a website that fits the management concept through research needs, page planning and design, column layout and other links. Standardize the website management by improving the management system, improving the management mechanism, and building a solid foundation for information security protection.Results:The revised website becomes not only an important window and bridge for external publicity and communication of the scientific research institutes, but also a concentrated embodiment of the achievements of information construction and management quality.Conclusions:Unified construction and management of the website can integrate resources, realize the coordination and efficiency of scientific research management, significantly improve the timeliness of information dissemination, promote the diversification of publicity modes, and improve the quality of scientific research services.
10.Advances in research on therapeutic strategies of targeting pancreatic cancer stroma
Xinyuan ZHOU ; Nan LIU ; Pan ZHANG ; Meirong HUO
Journal of China Pharmaceutical University 2021;52(6):653-662
Pancreatic cancer stroma plays a critical role in tumor progression, invasion, metastasis and resistance.Targeting tumor cell alone could not meet the demand for prolonging patients'' survival.Growing studies have laid emphasis on developing combined regimens between targeting pancreatic cancer stroma and chemotherapy, radiotherapy and immunotherapy.We are faced with some new opportunities in spite of the great challenges brought to the research and development of targeting drugs owing to the complicated stroma components, crosstalking signal pathways and abnormal angiogenesis of pancreatic cancer.In this article, recent advances in therapeutic strategies of targeting pancreatic cancer stroma are reviewed and analyzed from the aspects of extracellular matrix (ECM), cancer associated fibroblasts (CAFs) and vessels, in the hope of providing some novel ideas for targeting therapy against pancreatic cancer.


Result Analysis
Print
Save
E-mail